ASIAN JOURNAL OF CLINICAL PERINATOLOGY AND PEDIATRIC BIOLOGY

VOLUME 1, 2026

Placental Mitochondrial Dysfunction and Energy Metabolism Alterations in High Risk Pregnancies

*Yuan Seng Wu[1] and Cynthia Shamini Dawson[2]

[1]Sir Jeffery Cheah Sunway Medical School and Sunway Microbiome Centre, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Malaysia

[2]Faculty of Liberal Arts, Humanities and Culture, Perdana University, Damansara Heights, Kuala Lumpur, Malaysia

*Correspondence: yuansengw@sunway.edu.my

Submitted: 08 Oct 2025, Revised: 28 Nov 2025, Accepted: 05 Feb 2026

https://doi.org/10.64799/ajcppb.V1.I1.10

Abstract

Metabolic stress during high-risk pregnancies is defined as a placental energy homeostasis disruption. With this, we examined the mitochondrial structure, respiration, and energy metabolism of the placenta in the context of preeclampsia, gestational diabetes mellitus, and intrauterine growth restriction. Since the analyses showed extreme mitochondrial ultrastructural anomalies, loss of respiration, and efficiency of the coupling and ATP synthesis processes in cross-sectioned high-risk placentas, we are addressing this phenomenon in the context of redox imbalance and the increased compensatory glycolytic metabolism. During this research, multidimensional correlation and predictive modeling helped us examine the continuum of the severity of adverse outcomes of pregnancies and pinpoint loss of energy metabolism and mitochondrial dysfunction. This abhorrent phenomenon of placental energy metabolism and increased glycolytic metabolism is a key characteristic of high-risk pregnancies. This research emphasizes the pragmatic nature of placental energy metabolism as a focus for innovative diagnostic and therapeutic strategies in obstetric care. The research results also provide a basis for risk stratification based on quantifiable placental maladaptation biomarkers.

Keywords: Placenta; Mitochondrial dysfunction; Energy metabolism; High-risk pregnancy; Oxidative phosphorylation; Biomarker-based risk stratification

1. Introduction

As a temporary organ, a placenta serves a primary function to enable an exchange of nutrients and metabolic signals to sustain fetal growth and supporting the adaption of the mother to pregnancy. Central to the regulation of placental functions are the placental mitochondria. Within each cell, mitochondria act as the main site where cellular energy is produced and step in as metabolic sensors and signaling centers. Placental mitochondria balance maternal nutrients, and oxygen and hormones to determine the energy supply to the fetus and therefore, play a crucial role in determining fetal growth and pregnancy outcome [1], [2].

Active transport processes across the placental barrier, including the transport of amino acids, the processing of glucose, the metabolism of lipids, and the exchange of ions, are powered by the adenosine triphosphate (ATP) produced, primarily, via mitochondrial oxidative phosphorylation [3]. In addition to ATP, placental mitochondria are involved in the regulation of redox balance, calcium signaling, steroidogenesis, and apoptosis, solidifying the multifunctional role of mitochondria in placental physiology [4]. The metabolic demands of pregnancy and the remodeling tissues of the placenta across the gestation period, necessitate the efficiency and adaptability of mitochondria to sustain a dynamic bioenergetic homeostasis [5].

The conditions of Preeclampsia, Gestational Diabetes Mellitus (GDM) and Intrauterine Growth Restriction (IUGR) are in fact validated as pregnancy complications that attempt to describe a unique set of stressors, beyond obstetric stressors. Preeclampsia, GDM and IUGR relate to similar features of stress, such as impaired nutrient acquisition and transport, oxygen dysregulation, placental inflammation, and increased oxidative stress [6], [7]. Because of their role in cellular respiration and energy (ATP) generation, metabolically active placental mitochondria are particularly sensitive to hypoxic conditions and inflammation. In fact, placental mitochondrial dysfunction, present in adverse outcomes of every pregnancy complication described above, is perhaps the most common pathophysiological mechanism of poor adverse pregnancy outcomes [8].

In Preeclampsia, altered placental perfusion and cycles of placental hyperoxia and hypoxia, are the dominant oxidative stressors to placental mitochondria. These stressors increase dysfunction of placental mitochondria electron transport chain (ETC), and increase the production of reactive oxygen species (ROS), and Adenosine Triphosphate (ATP) synthesis inefficiency [9]. Increased oxidative stress (impaired placental mitochondria ETC) increases placental inflammation, ultimately forming a vicious cycle that increases placental dysfunction [10]. In IUGR (similarly to preeclampsia and GDM), the mitochondrial dysfunction of placental failure is characterized by a lack of functional placental energy which is a persistent state of intrauterine (fetal) energy depletion and diverts intrauterine growth (fetal growth) [11].

Gestational diabetes mellitus is a related but separate metabolic state involving hyperglycemia, insulin resistance, and disrupted lipid metabolism. Mitochondria play a critical role for embryo development, and in a placental

context, are critical for maintaining a state of metabolic flexibility [12]. Excessive placental nutrients can overwhelm their oxidative phosphorylation, resulting in a shift to less efficient energy producing glycolytic pathways [13]. This is likely to reduce ATP for active transport and alter redox balance, all of which adversely impacts fetal growth and development. Therefore, it appears that both too many and too few nutrients can negatively impact placental mitochondrial function and energy metabolism.

Mitochondrial dysfunction and oxidative stress in the placental tissues are key elements of the placental and fetal sequelae in high-risk pregnancies. Normal, placental tissue, and cellular development is driven by the limited expression of mitochondrial derived reactive oxygen species (ROS) [14]. However, an oxidative stress is the consequence of too many ROS that overwhelm the antioxidant capacity of tissues and damage all cellular components. Under both hypoxic and hyperoxic conditions, placental mitochondria are leading indicators of an increased ROS in the tissue. In high-risk pregnancies, the increased generation of ROS in mitochondria has been linked to the loss of lipids, proteins, and the mitochondrial DNA, which impairs the function and the life-span of mitochondria [15].

There is a two-way relationship between oxidative stress and ATP synthesis. Mitochondrial injury decreases oxidative phosphorylation and increases electron leakage, further raising ROS generation and reducing ATP production [16]. This vicious cycle severely impairs the ability of the placenta to meet the heightened energetic requirements of pregnancy, particularly during the later stages of gestation when the rate of fetal growth is at its peak. ATP deficiency in the placenta may restrict active transport mechanisms, hormone production, and cell turnover, thereby aggravating placental insufficiency and the associated negative outcomes [17].

Metabolic inflexibility is yet another characteristic of placental mitochondrial dysfunction in high-risk pregnancies. Ideally, placental mitochondria can switch between the usage of various substrates, including glucose, fatty acids, and amino acids, depending on maternal and fetal requirements. In the adverse condition of placental mitochondrial dysfunction, this ability is diminished, and as a result, substrates are used inefficiently and metabolic intermediates become over-accumulated [18]. Metabolically induced oxidative stress and hypoxic conditions may become a self-reinforcing negative cycle that further limit ATP synthesis and cause bioenergetic collapse.

Recent studies also highlight abnormal placental function linked with disrupted processes for mitochondrial formation and distribution. Increased placental amounts of mitochondria and abnormal changes in the mitochondria's size and shape from fission and fusion have been reported in high-risk pregnancies. This indicates in higher-order pregnancies there is both negative structural and functional placental remodeling [19], [20]. These changes may reflect an adaptive response to a stressed metabolism or, on the other hand, may reflect further negative changes that worsen mitochondrial inefficiency.

Thus, to explain the bioenergetic changes that occur in complicated pregnancies, it is critical to understand the mechanisms involved in the alteration of mitochondria in the placenta at the cellular level. This said, placental mitochondrial dysfunction has negative implications beyond the duration of the pregnancy. Fetuses may develop a higher risk for metabolic and cardiovascular diseases later in life due to energy deficit, oxidative stress, and metabolic programming during critical developmental windows that are the result of altered placental energy metabolism. These factors all can contribute to poor placental mitochondrial function [21]. Thus, mitochondrial health in the placenta is critical not only for the short-term outcomes of the pregnancy but also for the long-term health of future generations.

Although the growing recognition of the role of mitochondria in placental pathology is helpful, there is insufficient understanding of how certain manifestations of mitochondria link to specific clinical phenotypes, as phenomena pertain to various high-risk pregnancy conditions. Studies have centered on specific functions of mitochondria, such as the production of reactive oxygen species (ROS) or the level of respiratory activity, without considering the measurement of these processes in relation to the bioenergetic dimension. Analyses that relate all three dimensions of the mitochondrial triad (structure, function, and output) to clinical dimensions of pregnancy risk are required [22].

In addition, the distinct approaches taken by studies, gestational age at sampling, and methods of analysis have caused heterogeneity that restricts comparison. The development of standardized frameworks that incorporate clinical stratification, along with mitochondrial functional assays and metabolic assessments, is needed to apply mechanistic understanding to clinically relevant outcomes [23]. These methodologies might lead to the development of mitochondrial biomarkers that differentiate between adaptive and maladaptive placental responses to metabolic stress.

In this context, the present study views placental mitochondria as key players in managing fetal energy provision and the adaptability of the pregnancy, especially under complex clinical scenarios. With the conceptualization of preeclampsia, GDM, and IUGR as states of metabolic stress, the study interweaves oxidative stress, ATP synthesis, and metabolic rigidity into a singular conceptual framework of placental dysfunction. This lens focuses on bioenergetic collapse as a critical pathway unifying multiple pregnancy-related disorders. [24].

This study aims to help understand the placental bioenergetic changes in a complex clinical setting, focusing on the changes in the structure and function of the mitochondria, bioenergetics, and the energy metabolism of the placenta. Understanding these relationships helps advance the development of biomarkers, risk assessment, and the prioritization of therapeutic targets. This study may help develop interventions to improve placental mitochondria dysfunction and the outcomes of high-risk pregnancies, benefiting maternal-fetal health from a life course perspective. [25].

2. Study Design and Mitochondrial Assessment Framework

This study aimed to identify the specific types of placental mitochondrial dysfunction and their corresponding changes in energy metabolism symptoms, viewing them as integrated bioenergetic phenomena instead of as separate and isolated molecular defects. The bioenergetic phenomenon framework purposely aligns clinical stratification with mitochondrial function and metabolic modeling so that placental bioenergetics can be interpreted in relation to the risk associated with the pregnancy. The framework supports mechanistic inference while sustaining translational relevance by contouring the study around standardized tissue management, reproducible mitochondrial assays, and clinically relevant cohort definitions.

Samples of the placenta were obtained from a clinically characterized group that included uncomplicated control pregnancies and those pregnancies that were considered to be clinically complicated and high risk due to preeclampsia, gestational diabetes mellitus, or intrauterine growth restriction. These conditions were chosen as they underrepresented both distinct clinical phenotypes as well as a placental metabolic stress pathway representative convergence. Table 1 summarizes the clinical characteristics of the study cohort, including gestational age at delivery, maternal body mass index, and the diagnostic and delivery outcome categories. Stratification by these characteristics facilitated the comparison of mitochondrial and metabolic parameters in the placental environments that were physiologically normal and those that were pathologically and stressed, while also controlling for major confounding variables. There was also an effort made to minimize variability in gestational age between groups to lessen the bias due to development on the mitochondrial measurements.

Table 1. Clinical characteristics of study cohorts

Characteristic	Control (n = 30)	High-risk (n = 45)	p-value
Gestational age (weeks), mean ± SD	38.9 ± 1.1	36.8 ± 2.4	<0.001
Maternal BMI (kg/m²), mean ± SD	24.1 ± 3.2	28.6 ± 4.8	<0.001
Preeclampsia, n (%)	0 (0)	18 (40.0)	—
Gestational diabetes mellitus, n (%)	0 (0)	15 (33.3)	—
Intrauterine growth restriction, n (%)	0 (0)	12 (26.7)	—
Cesarean delivery, n (%)	9 (30.0)	26 (57.8)	0.02
Birth weight (g), mean ± SD	3250 ± 410	2480 ± 520	<0.001

Placental tissue sampling was conducted according to a strictly defined protocol. This was to optimize for preservation of both the mitochondria and their metabolic status. Tissue was obtained immediately post delivery from the fetal side of the placenta and was from tissue that lacked any gross visible infarct, calcifications, or hemorrhages. Sampling sites were selected to a defined distance from the umbilical cord so as to minimize any sampling bias in the heterogeneity of the mitochondria and metabolic activity. Great care was also taken with the speed and method of tissue processing, and tissue was rinsed with an ice-cold isotonic buffer and was scanned for any residual blood. Tissue was then earmarked for the desired downstream analyses. This approach also was optimized for minimizing post delivery ischemia and enzymatic degradation in order to protect the functional measurements of the mitochondria.

Mitochondrial isolations were conducted by means of a differential centrifugation, which was specific to the trophoblast engorged placental tissue. The removal of mitochondria at the homogenization step was designed to balance the yield and the integrity of the mitochondria. This was to ensure that intact and functionally competent mitochondria would be retrieved for downstream measurements of respiration and various enzymatic assays. Mechanical homogenization was kept to a minimum in order to preserve a majority of the mitochondria, and the centrifugation parameters were kept constant for all of the samples. The mitochondria were then analyzed on their relative functional parameters after establishing their protein content, so as to achieve a relative quantitative comparison with one another and across the various clinical groupings. This also provided an opportunity to preserve the context of the placental in vivo metabolism.

The functional assessment of isolated placental mitochondria centered on the primary parameters of oxidative phosphorylation and bioenergetic efficiency. Assessments of mitochondrial respiration were performed under basal state, substrate, and inhibitor state challenges, and were designed to investigate the capacity of the electron transport chain, coupling efficiency, and reserve respiratory power. These measurements were designed to capture the 'routine' energetic state and the 'responsive' state of the mitochondria to an increased metabolic demand. Evaluation of respiration across different functional states differentiates adaptive from pathological mitochondrial responses on the spectrum of metabolic stress.

The capacity to produce ATP was measured simultaneously with respiration to quantify energetic output. This assessment was required because the consumption of oxygen, while important, is an imperfect measure of bioenergetic efficiency because the mitochondria may demonstrate paradoxical respiration with insufficient ATP production due to coupling to respiration. Assessment of the rate of ATP production along with parameters of respiration provides the capacity to pinpoint bioenergetic shortcomings, which are especially important in the context of high-risk pregnancies, which shift the demand of the placental to be energetically expensive. These parameters measure the extent to which mitochondrial functioning is able to support the energetic demands of the placenta for active transport, hormone production and cell turnover.

Integrative understanding of the context of oxidative stress will continue to inform the understanding of function of mitochondria. Under altered oxygen environment and nutrient imbalance, placental mitochondria are a significant source of reactive oxygen species. While placental development and signaling are supported by the physiological role of the ROS, excessive reactive oxygen species can compromise oxidative phosphorylation by damaging the mitochondria. As a result, the framework positions the data pertaining to the ATP synthesis and respiration of the mitochondria within a broad redox framework, which positions further analysis to explore the interconnections between the inefficiency of mitochondria, burden of oxidative stress, and dysregulation of metabolism.

In a bid to extend data of mitochondrial functionality to adverse outcomes at the tissue level, a corresponding layer of analysis, placental metabolic profiling, was implemented. ATP levels and cellular redox state were used to determine whether the changes in the function of the mitochondria translated into negative changes in the metabolism within the placental tissue. These metabolic outcomes are critical for understanding the imposition of the mitochondria functionalities; in placental tissues a preserved tissue energy level is indicative of metabolic pathways at work, and a tissue energy level deficiency or low tissue energy level, is indicative of bioenergetic failure. Metabolic and mitochondrial metrics fusion enables a comprehensive evaluation of energy metabolism in the placenta.

Figure 1 illustrates the overall analytical workflow. In this workflow, the LIMS style pipeline is shown with integrated placental sampling, mitochondrial isolation, functional assays, and metabolic modeling. The workflow focuses on reproducibility, traceability, and the integration of data on different levels. Each analytical step is processed into the subsequent step, and ensures that the raw functional measurements captured are contextualized with respect to the metabolic and clinical frameworks. The LIMS style representation focuses on the analytical processes and suggests that the workflow is scaleable to higher cohorts and or multi-centered studies.



Figure 1. Integrated analytical workflow for placental mitochondrial and metabolic profiling

The analysis of data was designed to be reflective of the varied levels or hierarchy of the data collected. The first round of analysis was directed at discerning the differences between the control and high risk pregnancy group while using the parameters outlined in Table 1, to pinpoint specific mitochondrial and metabolic parameters impacted by the risk pregnancy associated status. In addition to the univariate comparisons, the analysis included

multivariate modeling techniques in order to evaluate and balance a number of functional and metabolic parameters into a composite profile of bioenergetics. The placental mitochondrial dysfunction is a multi-faceted problem that is not captured by a single parameter, and instead, it is a coordinated dysfunction that occurs to a number of facets of the energy metabolism.

The study design emphasized quality control and reproducibility. Standard operating procedures were followed for all aspects of tissue handling, mitochondrial isolation, assay execution, and data normalization. To evaluate and minimize technical variability and ensure consistency within and across experimental runs, internal controls and replicated measurements were implemented. The stepwise methodology shown in Figure 1 provides clear sample and data tracking, thereby minimizing the risk of batch and bias from the analysis. These factors increase the reliability of the differences being due to biological variation rather than technical variation.

The underlying principle of the integrated framework is to enable the placement of placental mitochondrial dysfunction as a clinically relevant indicator of metabolic stress in pregnancy rather than as an isolated finding from the lab. By matching mitochondrial function to the metabolic state and clinical phenotype, the study design provides meaning to bioenergetic changes in the context of pregnancy and associated risks. This methodology facilitates the detection of mitochondrial signatures that may differentiate the adaptive placental responses from the maladaptive dysfunction in various high-risk scenarios.

3. Results: Placental Mitochondrial Structural and Functional Alterations

Integrity and performance of placental mitochondria emerged as distinguishing features explaining the difference between normal pregnancies and high-risk pregnancies complicated by metabolic stress. Structural and functional assessments showed that the alterations of the mitochondria in high-risk placentas are neither incidental, nor uniform, but are, in fact, the coordinated disruption of multiple facets of organelle structure, function, and bioenergetics. In this section, the aim is to integrate ultrastructural descriptions and aggregated bioenergetic data to explain the various manifestations of mitochondrial dysfunction and its contribution to the imbalanced energy of the placenta.

Mitochondrial structural analysis of placentas showed the presence of marked mitochondrial heterogeneity and differences in morphology between control and high-risk pregnancies. Figure 2 illustrates that well-defined double membranes, densely packed and orderly cristae, and relatively uniform size distribution, is demonstrative of the presence of efficient oxidative phosphorylation in the mitochondria of control placentas. Conversely, high-risk pregnancy placentas demonstrated increased mitochondrial ultrastructural abnormalities that included mitochondrial swelling, disrupted, and fragmented cristae, and irregular membrane contours. The changes were also characterized by altered mitochondrial density within trophoblast cells suggesting that metabolic stress conditions lead to dysregulation of mitochondrial biogenesis and turnover.



Figure 2. Mitochondrial ultrastructure and density alterations in high-risk placentas

High-risk placentas showed varying degrees of diminished mitochondrial density, in the absence of sufficient structural compromise, or the presence of sufficient structural compromise. Such patterns highlight the potential adaptive responses, suggesting that placentas with increased structural compromise are attempting to offset some form of functional inefficiency. In contrast, some placentas showed a net loss of mitochondria resulting from oxidative damage and the inability to biogenetically replenish. The fact that such structural changes occur is of great importance, as the arrangement of the inner mitochondrial membrane and the associated cristae, are some of the primary site of the mitochondrial respiratory chain and ATP synthase, thus linking structural arrangement to functional performance.

There is a remarkable alignment between the ultrastructural irregularities and changes in oxidative stress and energy demand during high-risk pregnancies. Mitochondria, particularly cristae, can swell and fragment as a consequence of both oxidative balance and membrane potential perturbations, highlighting the loss of ability to maintain the required proton gradients to synthesize ATP. With this in mind, Figure 2 reinforces the placental mitochondrial dysfunction hypothesis at an ultra-structural level in high-risk pregnancies as a precursor to further functional deficits.

Details for figure 3 and table 2 describe how the function analytical responses of the separated placental mitochondria concluded the presence of considerable alterations in bioenergetics and overall respiration potential of the mitochondria. Placental mitochondria in the high-risk category displayed statistically significant differences in the control group for the basal respiration parameter, typically representing the value of the basal level of respiration in the mitochondria. Several of the high-risk samples displayed a decrease in basal respiration, suggesting a decrease in the activity of the mitochondria, even in the presence of stimuli. Reduced basal respiration entails a primary obstacle for the mitochondria, indicative of some form of alteration in the structural

integrity of the electron transport chains, or, in the in vivo, an inadequate functioning of some of the mitochondria involved in the recycling of substrates.



Figure 3. Placental mitochondrial respiratory function and ATP production capacity

Table 2. Key mitochondrial functional parameters

Parameter	Control pregnancies (mean ± SD)	High-risk pregnancies (mean ± SD)	p-value
Basal respiration (pmol O_2·min^{-1}·mg^{-1} protein)	95.4 ± 12.1	61.8 ± 14.6	< 0.001
Maximal respiration (pmol O_2·min^{-1}·mg^{-1} protein)	181.2 ± 21.5	109.6 ± 25.3	< 0.001
ATP-linked respiration (pmol O_2·min^{-1}·mg^{-1} protein)	159.7 ± 18.9	92.4 ± 19.7	< 0.001
Proton leak (pmol O_2·min^{-1}·mg^{-1} protein)	18.6 ± 4.2	31.9 ± 6.5	< 0.001
Respiratory control ratio (RCR)	4.12 ± 0.58	2.38 ± 0.64	< 0.001
Coupling efficiency (%)	74.8 ± 6.9	54.2 ± 8.1	< 0.001

Placentas deemed high-risk demonstrated a statistically significant differences in Maximal respiration for the control group after the difference in the pharmacological rotation closing of the electron transport within the chain mechanisms to the mitochondria. The high-risk condition's limitation of maximal respiratory capacity is indicative of a decreased potential reserve, which suggests the mitochondria of high-risk conditions are incapable of responding to demands for an increase in energy. This is important during the latter part of the pregnancy because of the demand increase due to the rapid growth of the fetus and the increased demand for placental transport. The high-risk condition's limitation of maximum recovery capacity of respiration is significant due to the fact of being a precursor to an increase in energy failure, which does show absence or shortage of energy, especially in the function of the placenta.

The high-risk placentas showed a disproportionate impact on ATP-linked respiration, which directly reflects the amount of oxygen consumed that is coupled to ATP synthesis. In the at-risk group, as noted in Table 2, there is less ATP-linked respiration for a given amount of total respiration, suggesting that there is less coupling between

electron transport and ATP production. If mitochondria are using up oxygen, then there should be less usable cellular energy. Such uncoupling could be due to membrane damage, increased (or altered) proton conductance, or inappropriate expression of the components of ATP synthase.

In high-risk placentas, the elevation of proton leak, which is the non-ATP–producing oxygen consumption caused by protons that re-enter the inner mitochondrial membrane, is the most notable for the most notable proton leak. Increased proton leak in high-risk placentas is a sign of mitochondrial dysfunction and oxidative stress, and implies that the membranes of the mitochondria are less intact and that the composition of the lipids has changed. Mild proton leak helps to prevent the production of reactive oxygen species but excessive leak reduces energetic efficiency and exacerbates ATP depletion. Therefore, the increased proton leak in high-risk placentas directly reduces their energy inefficiency, and may also lead to increased oxidative stress due to cycling.

The ratio of maximal to basal respiration, known to be integrated indicators of the efficiency and adaptability of the mitochondria, is called the respiratory control ratio (RCR). We found that hi-risk placentas had considerably lower RCR compared to controls, which is presented in Table 2. The RCR reduction is due to both the decreased maximal respiratory capacity and the changes in basal activity. Therefore, the conclusions drawn that the performance of the mitochondria is compromised at all levels is reinforced. An RCR that is lower denotes a lack of flexibility and resilience of the mitochondria, which in turn restricts the placentas ability to buffer metabolic stress.

Oxygen consumption, coupling, and ATP synthesis, functional findings illustration in clinical groups show the profiles in figure 3. The mean differences and greater variation of mitochondrial function in high risk placentas is indicated by the MATLAB style representations. This variability signifies a range of dysfunction in the mitochondria, perhaps due to disease severity, duration of stress, or compensatory ability. Preserved respiration in placentas that had not yet fully attained the lower ATP synthesis efficiency and un oxidative phosphorylation of respiration is a critical point to consider.

Based on the integrated changes on the structure and function of placental mitochondria, we propose a model of placental mitochondrial dysfunction as the result of interrelated processes. Structural damage on cristae and membranes leads to disorganization of the electron transport chain, which in turn causes a decline in respiratory efficiency and an increase in electron leakage. This cycle of mitochondrial damage causes and is caused by oxidative stress and functional decline. The residual state of bioenergetic inefficiency leads to a deficit of ATP and thereby to insufficient performance of vital placental functions, including active transport of nutrients, the synthesis of hormones, and cellular upkeep.

Crucially, these changes in mitochondria are not limited to one high-risk condition, but mitochondrial dysfunction has the same pattern and magnitude across preeclampsia, gestational diabetes mellitus, and

intrauterine growth restriction. The presence of similar functional and structual changes of mitochondria stems from the common pathway of bioenergetic disruption in the mitochondria stemming from accumulating metabolic stress. The functional and structural changes in bioenergetic mitochondria, coupled with a deficit in compensatory biogenesis and an increase in mitochondrial uncoupling, collectively account for, in large part, the differing clinical phenotypes for these conditions.

The failure of placental energy metabolism can also be to an extent explained by the relationship between the structure and function of mitochondria. With disrupted cristae architecture, there is a diminishing of the surface that is available to the oxidative phosphorylation complexes. Furthermore, there is a membrane rupture that increases the proton leak and reduces the membrane potential. Taken together, these modifications reduce the ATP yield and oxygen consumed, pushing the placenta into an inefficient energy state. In high-risk pregnancies, where the delivery of nutrients and oxygen may be limited, such inefficiencies can be detrimental to the energy available to the fetus.

Figures 2 and 3, and Table 2, together illustrate, by making explicit the correlation between ultrastructural abnormalities and bioenergetic deficits, that the placental mitochondria for high-risk pregnancies deeply structural and deeply dysfunctional. The evidence shown indicates that the changes to the mitochondria are more than just secondary indicators of the placental pathology. Rather, they are actively and directly interfacing with the dysfunctional energy metabolism. This unified approach is critical for understanding the changes to the mitochondria as the cause of the placental insufficiency and not merely as epiphenomena.

4. Energy Metabolism Dysregulation and Clinical Correlates

The measurable disruptions in placental energy metabolism demonstrate the impact of mitochondrial impairments. It exemplifies the importance of dysfunction in mitochondria in the placental changes that occur in energy metabolism in higher risk pregnancies. Instead of showing deficits in specific pathways, the results show changes in the overall cellular energy status, the redox state, and the metabolic adaptation that reveal integrated shifts. These shifts help explain changes in mitochondria and the relevant clinical outcomes in pregnancy.

High-risk placentas show most consistently altered ATP homeostasis. Declines in the mitochondrial respiratory capacity and the coupling efficiency corresponded to lower levels of placental ATP, pointing to an inability of the oxidative phosphorylation to meet the energy demands. The energy deficits varied and followed a gradient of mitochondrial dysfunction. Severe impairment of mitochondria in the placentas led to the most ATP depletion. The placentas with moderate mitochondrial dysfunction seem to have some adaptive, compensatory metabolism, preserved ATP levels. These results are summarized in Table 3, where each level of mitochondrial dysfunction is associated to a specific placental metabolic marker.

Table 3. Placental metabolic markers stratified by pregnancy risk status

Metabolic marker	Low risk (mean ± SD)	Moderate risk (mean ± SD)	Severe risk (mean ± SD)	p-value (trend)
ATP content (nmol·mg^{-1} protein)	8.6 ± 1.1	6.2 ± 1.3	3.9 ± 1.0	< 0.001
NAD^+/NADH ratio	0.92 ± 0.08	0.71 ± 0.09	0.49 ± 0.07	< 0.001
Lactate concentration (µmol·g^{-1} tissue)	1.8 ± 0.4	3.1 ± 0.6	5.2 ± 0.9	< 0.001
Glucose uptake rate (nmol·min^{-1}·mg^{-1})	4.9 ± 0.7	6.3 ± 0.8	7.8 ± 1.0	< 0.001
Oxidative phosphorylation contribution (%)	71.4 ± 6.5	56.8 ± 7.1	38.6 ± 6.9	< 0.001
Glycolytic reliance index (a.u.)	0.34 ± 0.09	0.61 ± 0.11	0.88 ± 0.13	< 0.001

Parallel to and interdependent with the disruption of placental metabolism is redox imbalance. The NAD^+/NADH ratio, an important measure of the redox state of the cell and the flow of the cell's metabolism through its mitochondria, is disrupted in high-risk pregnancies. Lower NAD^+/NADH ratios signify oxidative metabolism of the cell and the accumulation of reduced equivalents that correspond to the decreased activity of the electron transport chain. This type of redox shift affects the amount of cellular energy (ATP), but more importantly, it affects the cellular signaling associated with stress, the production of new mitochondria, and the expression of enzymes coded in cellular metabolism genes. The redox imbalance explains the broad scope of its impact with the dysfunction of the mitochondria.

The placentas labeled as 'high risk' showed signs of metabolic inflexibility as demonstrated by the accumulation of lactate. High levels of lactate signal a shift towards a more glycolytic pathway as a compensatory mechanism due to the inability to perform oxidative phosphorylation. Glycolysis can alleviate some of the issues by generating ATP, however, it inefficiently produces byproducts that stress the system further. The accumulation of lactate in the placenta, as seen in Table 3, illustrates a dependence on anaerobic pathways, or even pseudo-anaerobic pathways, despite the presence of oxygen. This reflects a metabolic profile of insufficient mitochondria. While such a shift may protect the short term availability of energy, it may also compromise the adequacy of the placental function as it allows an accumulation of a further buffer to the function of the placenta.

The relationship is depicted in Figure 4, which presents a correlation surface that integrates the energy deficit of the mitochondria and the levels of ATP, lactate, NAD^+ and NADH. The multidimensional surface illustrates that these markers intersect and pass through a surface of progressively deteriorating metabolism. Aggravated mitochondrial dysfunction is insufficient in explaining the levels of these metabolic markers in isolation. Ultimately, as the efficiency of the mitochondria decreases, the levels of ATP decreases concomitantly with the levels of NAD and increase of lactate. This indicates a metabolic response that is tightly coupled as opposed to pathway failures that is highly compartmentalized.



Figure 4. Correlation surface linking mitochondrial dysfunction to placental energy metabolism markers

Figure 4 shows the impacts of metabolic dysregulation. Slight impairment of the mitochondria led to small ATP reductions and minor redox changes. This suggests that for some level of mitochondrial impairment, the placental metabolism may still operate normally. For other levels of mitochondrial impairment, ATP synthesis and redox levels decreased, and the amount of metabolic disorder that occurred increased disproportionately to the changes in mitochondrial function. This highlights the extraordinary changes that may happen to placental metabolism when additional levels of compensation are applied and explains why, in some high-risk pregnancies, the outcomes are stable but in others, the outcomes are very poor.

There are metabolic changes that are associated with outcomes of pregnancies. These changes are the reason why the outcomes of the pregnancies are significant. The placentas that are the most dysregulated in metabolism most commonly co-occur with the most severe outcomes, such as fetal growth restriction, preterm birth, and high neonatal morbidity. Conversely, placentas exhibiting mild variations to energy metabolism dysregulation commonly co-occur with better outcomes or less severe outcomes. This suggests that placental energy metabolism is an intermediary phenotype correlating mitochondrial dysfunction to clinical risk.

We constructed a multivariate metabolic risk model to evaluate the predictive potential of metabolic and mitochondrial parameters, as presented in Figure 5. It employs the parameters from mitochondrial respiration, AT, redox, lactate, and pregnancy risk status. Instead of utilizing one or two biomarkers, the model encompasses the collective effect of several bioenergetic parameters, honouring the systems-level approach to placental metabolism. The classification surface illustrates the low and high-risk pregnancy categories, while the intermediate zones highlight the presence of moderate dysfunction.



Figure 5. Predictive metabolic risk model for adverse pregnancy outcomes

The metabolic risk model serves as a feedback mechanism as it demonstrates the performance of predictive metabolic placental models. It identifies pregnancies at risk of adverse outcomes through the innovative integration of functional mitochondrial parameters and metabolic downstream effects. The predictive metabolic risk model is far more beneficial than the sum of its parameters as it is aligned with the systemic placental biochemical dysfunction. Hence, in its most basic level, Figure 5 serves as a guide for transforming placental bioenergetic data into risk stratification models for clinical purposes.

Table 3 provides additional details regarding the modeling approach by showing placental metabolic markers by low, moderate, and severe mitochondrial dysfunction. The table illustrates ATP, NAD^+/NADH ratio, and lactate levels and the statistically significant differences across the categories. The table reinforces the concept of thresholds of metabolic severity and offers an applicable guide for assessing metabolic levels, mitochondrial activity, and pregnancy risk.

These findings hold potential for a wider appreciation of placental adaptation and placental failure. Disruption of ATP supply and redox balance does not have an effect that is simply disruptive to energy metabolism. A range of integral placental functions from active nutrient transport, hormone synthesis, angiogenesis, and cellular integrity, is all predicated on robust energy metabolism. The metabolic inflexibility observed in high-risk placentas most likely contributes to impaired placental signaling, altered vascular responses, and an inability to buffer environmental stressors.

The strong relationship between metabolic dysregulation and mitochondrial dysfunction shows potential points of intervention. Improving mitochondrial efficiency, restoring redox balance, and enhancing metabolic flexibility may help protect placental function during high-risk pregnancies. Although the therapeutic implications are outside the current scope, the significant relationships made in this analysis justify further research aimed at modulating mitochondria and metabolism to reduce risks.

5. Conclusion

This research study places mitochondrial dysfunction in the placenta as a common biological mechanism connecting diverse high-risk pregnancy phenotypes such as maternal preeclampsia, gestational diabetes mellitus, and intrauterine growth restriction. From the ultrastructural, functional and metabolic integration, the findings show that the mitochondrial dysfunction in the placenta is not a secondary or ancillary phenomenon, but is a primary cause of the maladaptive response of the placenta. This means that the breakdown of mitochondrial structure, diminished capability to perform mitochondrial respiration, and ineffective cellular respiration resulting in ATP (energy) deficits all contribute to the placenta's energy- deficit and compromised capacity to respond to the high energetic demands of late gestation. This means that the cellular bioenergetics of the placenta directly correlates to negative pregnancy outcomes.

Perhaps the most notable declaration which can be derived from this study is the collapse of the mitochondria of the placenta and the accompanying changes of placental energy metabolism and the ATP deficiency collapse in the mitochondria to be the first identifiable bio-pathologic target. The changes that occur in a continuum to the severity of the level of the dysfunction of the mitochondria that occur may occur in the ATP, the oxidative and reductive balance, and the metabolic flexibility. The continuum of changes can in fact occur unaccompanied by any clinically identifiable regression, thereby, describing the condition of placental scarcity and distilled bioenergy deficiency as a proximal condition, which from the preclinical state of the placental and fetal compromise, a sufficient and dischargeable bioenergy deficiency. The deficit is described as a consequence of the proximate condition. The identification of non-linear thresholds in metabolic deterioration further exemplifies the lack of available compensatory reserve of placental mitochondria, which can be utilized, once critical cellular dysfunction of the placental mitochondria is reached.

What makes this study really valuable is the fact that it combines all functions of mitochondria with their respective metabolic pathways for effective differentiation of varying degrees of risks associated with the complexity of pregnancies. The metabolic risk framework introduced in this study is one of the first attempts of its kind, where a multidimensional bioenergetics model is translated into clinically actionable outcomes, a level of sophistication that even surpasses singular biomarker models. It is also further substantiated in guiding assessment of placental bioenergetics, in which the mitochondrial and metabolic signatures may aid in the early identification of pregnancies with increased risk for adverse outcomes.

When considered jointly, the results highlight the application of placental mitochondria with respect to obstetric medicine. It also frames high-risk pregnancies as bioenergetic deficits, laying the groundwork for research examining mitochondrial diagnostics and therapies. Although potential therapeutic avenues lie outside the scope of this study, the notable link between mitochondrial deficits, energetic metabolism, and increased clinical risk correlates strongly and provides a framework for developing biomarker-based monitoring and other strategies to optimize outcomes for mothers and babies in high-risk pregnancies.

References

1. San Juan-Reyes, Sindy, et al. "Oxidative stress in pregnancy complicated by preeclampsia." *Archives of biochemistry and biophysics* 681 (2020): 108255.
2. Gaccioli, Francesca, and Susanne Lager. "Placental nutrient transport and intrauterine growth restriction." *Frontiers in physiology* 7 (2016): 40.
3. Illsley, Nicholas P., and Marc U. Baumann. "Human placental glucose transport in fetoplacental growth and metabolism." *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1866.2 (2020): 165359.
4. Glancy, Brian. "Visualizing mitochondrial form and function within the cell." *Trends in molecular medicine* 26.1 (2020): 58-70.
5. Nugent, Bridget M., and Tracy L. Bale. "The omniscient placenta: metabolic and epigenetic regulation of fetal programming." *Frontiers in neuroendocrinology* 39 (2015): 28-37.
6. Staff, Anne Cathrine. "The two-stage placental model of preeclampsia: An update." *Journal of reproductive immunology* 134 (2019): 1-10.
7. Fisher, Susan J. "Why is placentation abnormal in preeclampsia?." *American journal of obstetrics and gynecology* 213.4 (2015): S115-S122.
8. Jahan, Fahmida, et al. "Placental mitochondrial function and dysfunction in preeclampsia." *International journal of molecular sciences* 24.4 (2023): 4177.
9. Hu, Xiang-Qun, and Lubo Zhang. "Hypoxia and mitochondrial dysfunction in pregnancy complications." *Antioxidants* 10.3 (2021): 405.
10. Schoots, Mirthe H., et al. "Oxidative stress in placental pathology." *Placenta* 69 (2018): 153-161.
11. Hu, Yucheng, et al. "Mitochondrial dysfunction and oxidative stress in selective fetal growth restriction." *Placenta* 156 (2024): 46-54.
12. Holland, Olivia, et al. "Placental mitochondrial function and structure in gestational disorders." *Placenta* 54 (2017): 2-9.
13. Fisher, Joshua J., et al. "Mitochondrial dysfunction in placental trophoblast cells experiencing gestational diabetes mellitus." *The Journal of Physiology* 599.4 (2021): 1291-1305.
14. Sies, Helmut. "Oxidative stress: a concept in redox biology and medicine." *Redox biology* 4 (2015): 180-183.
15. Aouache, Rajaa, et al. "Oxidative stress in preeclampsia and placental diseases." *International journal of molecular sciences* 19.5 (2018): 1496.
16. Nicholls, David G. "The pancreatic β-cell: a bioenergetic perspective." *Physiological reviews* 96.4 (2016): 1385-1447.
17. Troisi, Jacopo, et al. "Placental metabolomics of fetal growth restriction." *Metabolites* 13.2 (2023): 235.
18. Grismaldo R, Adriana, et al. "Placental mitochondrial impairment and its association with maternal metabolic dysfunction." *The Journal of Physiology* (2024).
19. Bartho, Lucy A., et al. "Mitochondrial transformations in the aging human placenta." *American Journal of Physiology-Endocrinology and Metabolism* 319.6 (2020): E981-E994.
20. Sferruzzi-Perri, Amanda N., et al. "Placental mitochondria adapt developmentally and in response to hypoxia to support fetal growth." *Proceedings of the National Academy of Sciences* 116.5 (2019): 1621-1626.
21. Poston, Lucilla, et al., eds. *Developmental origins of health and disease*. Cambridge University Press, 2022.
22. Kwon, Eun Jin, and Young Ju Kim. "What is fetal programming?: a lifetime health is under the control of in utero health." *Obstetrics & gynecology science* 60.6 (2017): 506.
23. Jahan, Fahmida, et al. "Placental mitochondrial function and dysfunction in preeclampsia." *International journal of molecular sciences* 24.4 (2023): 4177.

24. Rodríguez-Rodríguez, Pilar, et al. "Implication of oxidative stress in fetal programming of cardiovascular disease." *Frontiers in physiology* 9 (2018): 602.
25. Correia, Yolanda, et al. "Placental mitochondrial function as a driver of angiogenesis and placental dysfunction." *Biological Chemistry* 402.8 (2021): 887-909.